Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
12 nov. 2019 16h30 HE
|
Abeona Therapeutics Inc.
Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019Publication of positive...
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
15 oct. 2019 09h15 HE
|
Abeona Therapeutics Inc.
Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular...
Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
09 août 2019 16h15 HE
|
Abeona Therapeutics Inc.
Five patients with MPS IIIB treated in the Transpher B Study of ABO-101 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust...
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
08 mai 2019 08h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data...
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
18 mars 2019 16h45 HE
|
Abeona Therapeutics Inc.
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 ...
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
11 févr. 2019 16h05 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for...
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
08 janv. 2019 13h00 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
06 déc. 2018 12h30 HE
|
Abeona Therapeutics Inc.
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV...
Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
13 nov. 2018 08h45 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
09 nov. 2018 16h20 HE
|
Abeona Therapeutics Inc.
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage...